* Fresh Tracks Therapeutics Inc FRTX.OQ FRTX.O is
expected
to show a rise in quarterly revenue when it reports results on
November 10.
* The Boulder Colorado-based company is expected to report
a
225.8% increase in revenue to $430 thousand from $132 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Fresh Tracks
Therapeutics
Inc is for a loss of $1.89 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Fresh
Tracks
Therapeutics Inc is $4.5, above its last closing price
of $1.73.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -1.46 -1.44 -0.01 Beat 99.3
Mar. 31 2022 -2.55 -2.59 -3.60 Missed -39.1
Dec. 31 2021 -3.84 -3.82 -2.70 Beat 29.4
Sep. 30 2021 -5.62 -7.20 Missed -28
Jun. -6.30 -5.62 -7.20 Missed -28
30 2021
Mar. 31 2021 -5.17 -5.17 -6.75 Missed -30.4
Dec. 31 2020 -4.05 -4.05 -6.75 Missed -66.7
Sep. 30 2020 -8.33 -8.32 -6.75 Beat 18.9
This summary was machine generated November 9 at 03:04 GMT. All
figures in US dollars unless otherwise stated